Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting
Immunovant announced that data from their Phase 2a trial of batoclimab in Graves' disease will be presented at the 2024 American Thyroid Association Annual Meeting in Chicago. The late-breaking oral presentation will showcase new data on both thyroid-specific and extrathyroidal manifestations of Graves' disease. The presentation titled 'Efficacy and Safety of the FcRn Inhibitor, Batoclimab, in Graves' Thyroidal and Extrathyroidal Disease: a Proof-of-concept Study' will be delivered by Dr. George Kahaly on November 1, 2024.
Immunovant ha annunciato che i dati del loro studio di Fase 2a su batoclimab nella malattia di Graves saranno presentati al Congresso Annuale dell'American Thyroid Association 2024 a Chicago. La presentazione orale dell'ultimo minuto mostrerà nuovi dati sia sulle manifestazioni specifiche della tiroide che su quelle extratiroidee della malattia di Graves. La presentazione, intitolata 'Efficacia e Sicurezza dell'Inibitore FcRn, Batoclimab, nella Malattia Tiroidea e Extratiroidea di Graves: uno Studio di Proof-of-concept', sarà tenuta dal Dr. George Kahaly il 1° novembre 2024.
Immunovant anunció que los datos de su ensayo de Fase 2a de batoclimab en la enfermedad de Graves se presentarán en la Reunión Anual de la Asociación Americana de Tiroides 2024 en Chicago. La presentación oral de último momento mostrará nuevos datos sobre las manifestaciones tanto tiroideas como extratiroideas de la enfermedad de Graves. La presentación titulada 'Eficacia y Seguridad del Inhibidor FcRn, Batoclimab, en la Enfermedad Tiroidea y Extratiroidea de Graves: un Estudio de Prueba de Concepto' será realizada por el Dr. George Kahaly el 1 de noviembre de 2024.
Immunovant는 그레이브스병에서 바토클리맙의 2a상 시험에 대한 데이터가 2024 미국 갑상선 학회 연례 회의에서 시카고에서 발표될 것이라고 발표했습니다. 최신 발표에서는 그레이브스병의 갑상선 특정 및 비갑상선 증상에 대한 새로운 데이터를 보여줍니다. '그레이브스의 갑상선 및 비갑상선 질환에서 FcRn 억제제인 바토클리맙의 효능 및 안전성: 개념 증명 연구'라는 제목의 발표는 2024년 11월 1일에 Dr. George Kahaly가 진행할 예정입니다.
Immunovant a annoncé que les données de leur essai de Phase 2a de batoclimab dans la maladie de Graves seront présentées lors de la Réunion Annuelle de l'American Thyroid Association 2024 à Chicago. La présentation orale de dernière minute mettra en avant de nouvelles données sur les manifestations spécifiques à la thyroïde ainsi que sur les manifestations extrathyroidiennes de la maladie de Graves. La présentation intitulée 'Efficacité et Sécurité de l'Inhibiteur FcRn, Batoclimab, dans la Maladie Thyroidienne et Extrathyroidienne de Graves : une Étude de Preuve de Concept' sera réalisée par le Dr George Kahaly le 1er novembre 2024.
Immunovant hat angekündigt, dass Daten aus ihrer Phase-2a-Studie zu Batoclimab bei Morbus Basedow auf dem Jahrestreffen der American Thyroid Association 2024 in Chicago präsentiert werden. Die nachgemeldete mündliche Präsentation wird neue Daten sowohl zu schilddrüfenspezifischen als auch zu extrathyroidalen Manifestationen der Graves-Krankheit zeigen. Die Präsentation mit dem Titel 'Wirksamkeit und Sicherheit des FcRn-Inhibitors Batoclimab bei der Schilddrüsen- und extrathyroidalen Erkrankung von Graves: Eine Machbarkeitsstudie' wird von Dr. George Kahaly am 1. November 2024 gehalten.
- Phase 2a trial data selected for late-breaking presentation at major medical conference
- None.
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that data from the Phase 2a trial of batoclimab in Graves’ disease will be the subject of an oral presentation of a late-breaking abstract accepted for the 2024 American Thyroid Association (ATA) Annual Meeting being held October 30 to November 3, 2024, in Chicago, Illinois. New data highlighting both thyroid-specific and extrathyroidal manifestations of Graves' disease will be presented.
Late-Breaking Oral Presentation Details:
| Title: | Efficacy and Safety of the FcRn Inhibitor, Batoclimab, in Graves’ Thyroidal and Extrathyroidal Disease: a Proof-of-concept Study |
| Presentation: | #0020 |
| Session: | #5 – Autoimmune Thyroid Disease |
| Date and Time: | Friday, November 1, 2024, 4:05pm – 5:05pm ET |
| Presenter: | George Kahaly, MD, PhD |
About Graves’ disease
Graves’ disease is an autoimmune disorder associated with the overproduction of thyroid hormones and is the most common cause of hyperthyroidism. Although Graves’ disease can affect any age group or gender, it occurs often in women younger than 40 years of age. In Graves’ disease, harmful IgG autoantibodies bind to and activate the thyroid-stimulating hormone receptor present on the thyroid gland, stimulating excess thyroid hormone production. Existing treatments, which include antithyroid drugs, radioactive iodine, and thyroid surgery, are aimed at reducing thyroid hormone levels to lessen the severity of symptoms. These treatments have remained largely unchanged for the past 70 years.
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.
Contact:
Renee Barnett, MBA
Chief Financial Officer
Immunovant, Inc.
info@immunovant.com
Source: Immunovant, Inc.
FAQ
When will Immunovant (IMVT) present its Phase 2a Graves' disease trial data?
What is the focus of Immunovant's (IMVT) Phase 2a trial presentation?
Who will present Immunovant's (IMVT) Graves' disease trial data at ATA 2024?
